BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights ...

Nov 15, 2024 · The company reported a net loss of $13.7 million for Q3 2024, although this was an improvement from a $50.5 million loss in Q3 2023. Cost of goods sold increased …

CouponFollow Extension

$13
OFF

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights ...

6 days from now

Nov 15, 2024 · The company reported a net loss of $13.7 million for Q3 2024, although this was an improvement from a $50.5 million loss in Q3 2023. Cost of goods sold increased …

yahoo.com

$13
OFF

Earnings Call: BioXcel Therapeutics Reports Q3 2024 Financials

6 days from now

Nov 14, 2024 · BioXcel Therapeutics had a net loss of $13.7 million for the third quarter of 2024, compared to a net loss of $50.5 million for the same period in 2023. Company used $16.3 …

investing.com

$40
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial

6 days from now

Nov 14, 2024 · Cash and cash equivalents totaled $40.4 million as of September 30, 2024. BioXcel Therapeutics will host a conference call and webcast today, November 14, 2024, at …

globenewswire.com

$40
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · Cash and cash equivalents totaled $40.4 million as of September 30, 2024. ConferenceCall and Webcast. BioXcel Therapeutics will host a conference call and webcast …

businessinsider.com

$13
OFF

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call ...

6 days from now

Nov 15, 2024 · BioXcel Therapeutics had a net loss of $13.7 million for the third quarter of 2024, compared to a net loss of $50.5 million for the same period in 2023. Company used $16.3 …

insidermonkey.com

75%
OFF

BioXcel Therapeutics (BTAI) Earnings Date And Reports 2024

6 days from now

5 days ago · BioXcel Therapeutics (BTAI) Earnings Date, Estimates & Call Transcripts. $0.58 +0.01 (+1.75%) (As of 11/18/2024 ET) Compare. Get BioXcel Therapeutics Earnings Alerts. …

marketbeat.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7M Public Offering

6 days from now

1 day ago · BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript. BioXcel announces common stock and warrants offering, no amount given. BioXcel Therapeutics …

seekingalpha.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7M Public Offering

6 days from now

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript; BioXcel announces common stock and warrants offering, no amount given; BioXcel Therapeutics GAAP EPS of -$0.32 …

msn.com

$0.26
OFF

Karyopharm Therapeutics (KPTI) Earnings Date And Reports 2024

6 days from now

Nov 15, 2024 · Karyopharm Therapeutics released Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.26, which topped analysts' consensus estimates of -$0.27 by $0.01. …

marketbeat.com

FAQs about BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights ... Coupon?

Does bioxcel Therapeutics (btai) have earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) reported earnings on Thursday, May, 9th. The company reported ($0.87) EPS, missing analysts' consensus estimates of ($0.68) by $0.19. The business earned $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. ...

Who owns bioxcel Therapeutics stock?

Top institutional owners of BioXcel Therapeutics stock include Vanguard Group Inc. (2.97%), Virtu Financial LLC (0.04%), and Concourse Financial Group Securities Inc. (0.00%). BioXcel Therapeutics' stock is owned by a number of retail and institutional investors. ...

Who are the major shareholders of BioXcel?

Major shareholders of BioXcel include Vanguard Group Inc. (2.97%), Virtu Financial LLC (0.04%), and Concourse Financial Group Securities Inc. (0.00%). Insiders who own company stock are BioXcel LLC, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta, and Vincent O'neill. ...

Is bxcl501 a breakthrough therapy?

BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. ...